Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (22588)	6/21/1998 9:28:00 PM
From: aknahow	Respond to of 32384

Indirectly from TSC thestreet.com a nice blurb from The Medicine Man. Current, but if everyone has seen it skip it. by George Stasen Ligand Pharmaceuticals: Hormones To Heal Make A Future Stock June 22, 1998 -- When it's too good to be true, it probably isn't, and as caveats go, that's one of the more reliable ones. However, for Ligand Pharmaceuticals (Nasdaq: LGND), what may have seemed too good to be true, is now materializing as true. Ligand's in-depth understanding of the multiple roles that hormones play in disease prevention and management has provided the company with extraordinary opportunities to create new drugs. That presents a problem of sorts. The range of current and possible therapies from cancer to diabetes is so wide that it invites skepticism. The antidote is a solid grounding in the company's underlying science, rather than the usual review of products under development or coming to market. Hormones are sometimes called "natural drugs" because they cause proteins to produce enzymes, which in turn control the way the body functions. The trouble is that the same hormone can cause different effects in different tissues and may trigger the production of enzymes that result in either positive or negative reactions. The negative reactions manifest themselves as undesirable side effects. In 1985, a series of discoveries by the company's scientific founder led to a clearer understanding of the way hormones exert their powerful effects. Since its founding in 1989, Ligand Pharmaceuticals has developed two technology platforms from which to pursue drug discovery. The first involves non-peptide, intracellular receptors and accounts for about 80% of the drug targets Ligand currently has under active development. The second technology involves peptide, extracellular receptors and comprises the remaining 20%. page 1 \| 2 \| 3 \| 4